Clinical trial
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
NCT00445003
Study timeline
Study start (unknown)2007-03-01Date precision: month
Registry last updated2016-08-26
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Proliferative Diabetic Retinopathyunresolved
Diabetic Macular Edemaunresolved
Interventions
RanibizumabDRUG · verified · RxNorm: ranibizumab
Triamcinolone AcetonideDRUG · verified · RxNorm: triamcinolone acetonide
Sham injectionBEHAVIORAL
Focal/grid laserPROCEDURE
Sponsors & collaborators
Jaeb Center for Health Researchlead sponsor
National Eye Institute (NEI)collaborator
Genentech, Inc.collaborator
Allergancollaborator
Mapped research locations
HoustonTexas, United States2BostonMassachusetts, United States2BaltimoreMaryland, United States2PortlandOregon, United States2MinneapolisMinnesota, United States2CharlotteNorth Carolina, United States2ColumbiaSouth Carolina, United States2New YorkNew York, United States1ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1San AntonioTexas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00445003 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.